27 high-performance-computing-postdoc Fellowship research jobs at University of Oxford in United Kingdom
Sort by
Refine Your Search
-
the implementation of the OpenSAFELY Talking Therapies programme. We provide the NHS England OpenSAFELY Service, providing secure research access to GP data and we have recently received a significant, multi-year
-
Motor Group, the Centre is led by Oxford strategy faculty Rafael Ramirez (Director) and Trudi Lang (Co-Director). Focusing on a discrete set of six high-impact themes, the Centre contributes significant
-
About the role We have an exciting opportunity to join the Draper Group in the Department of Paediatrics as our Clinical Research Fellow – Malaria Vaccine Programme. This role is focused
-
The Oxford School of Global and Area Studies (OSGA) wishes to appoint a full- time fixed term Senior Research Fellow and Programme Manager in Taiwan Studies. About the Role: The postholder will be a
-
. Remote working may be feasible depending on the nature of work tasks being performed. You will be working closely with Professor Regent Lee’s team. You will be carrying out research for different research
-
the College’s research programme, as well as being able to teach high-achieving graduate students. Additionally, they will possess excellent oral and written communication and interpersonal skills and
-
Translational Myeloma Centre (OTMC) is seeking to appoint a motivated and enthusiastic Clinical Research Fellow to join its dynamic and expanding programme of translational research in myeloma. This is an
-
postholder will be Director of the CDT programme, until September 2033 in the first instance, as this is the period for which funding from the Ellison Institute of Technology is confirmed. The successful
-
Motor Group, the Centre is led by Oxford strategy faculty Rafael Ramirez (Director) and Trudi Lang (Co-Director). Focusing on a discrete set of six high-impact themes, the Centre contributes significant
-
Fungal infections are a growing threat to planetary health and, in human medicine, the elderly and immunocompromised are a high-risk group. Resistance to the few existing treatments is increasingly